1. CD4+ Tumor infiltrating lymphocytes are prognostic and independent of R‐IPI in patients with DLBCL receiving R‐CHOP chemo‐immunotherapy. Issue 4 (5th March 2013) Authors: Keane, Colm; Gill, Devinder; Vari, Frank; Cross, Donna; Griffiths, Lynn; Gandhi, Maher Journal: American journal of hematology Issue: Volume 88:Issue 4(2013:Apr.) Page Start: 273 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia. Issue 12 (December 2014) Authors: Mulligan, Stephen P.; Karlsson, Karin; Strömberg, Mats; Jønsson, Viggo; Gill, Devinder; Hammerström, Jens; Hertzberg, Mark; McLennan, Roger; Uggla, Bertil; Norman, John; Wallvik, Jonas; Sundström, Gunnel; Johansson, Hemming; Brandberg, Yvonne; Liliemark, Jan; Juliusson, Gunnar; for the Scandinavi... Journal: Leukemia & lymphoma Issue: Volume 55:Issue 12(2014:Dec.) Page Start: 2769 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. High serum levels of CD178 (soluble FasL) predict for inferior progression free survival in chronic lymphocytic leukemia treated with fludarabine-based chemotherapy. Issue 10 (24th August 2019) Authors: Tate, Courtney; Burgess, Melinda; McMillan, Nigel A.; Saunders, Nicholas A.; Cheung, Catherine; Gill, Devinder; Mollee, Peter Journal: Leukemia & lymphoma Issue: Volume 60:Issue 10(2019) Page Start: 2563 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Issue 1 (January 2019) Authors: Moreno, Carol; Greil, Richard; Demirkan, Fatih; Tedeschi, Alessandra; Anz, Bertrand; Larratt, Loree; Simkovic, Martin; Samoilova, Olga; Novak, Jan; Ben-Yehuda, Dina; Strugov, Vladimir; Gill, Devinder; Gribben, John G; Hsu, Emily; Lih, Chih-Jian; Zhou, Cathy; Clow, Fong; James, Danelle F; Styles, ... Journal: Lancet oncology Issue: Volume 20:Issue 1(2019) Page Start: 43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Identifying an obinutuzumab resistant subpopulation of monocyte-derived-macrophages from patients with CLL. Issue 11 (18th September 2020) Authors: Burgess, Melinda; Chen, Yu Chen Enya; Mapp, Sally; Mollee, Peter; Gill, Devinder; Saunders, Nicholas A. Journal: Leukemia & lymphoma Issue: Volume 61:Issue 11(2020) Page Start: 2738 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Prognostic value of ZAP‐70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometry. Issue 2 (8th November 2013) Authors: Adams, Rebecca L. C.; Cheung, Catherine; Banh, Raymond; Saal, Russell; Cross, Donna; Gill, Devinder; Self, Marlene; Klein, Kerenaftali; Mollee, Peter Journal: Cytometry Issue: Volume 86:Issue 2(2014) Page Start: 80 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Issue 10 (October 2015) Authors: Keane, Colm; Vari, Frank; Hertzberg, Mark; Cao, Kim-Anh Lê; Green, Michael R; Han, Erica; Seymour, John F; Hicks, Rodney J; Gill, Devinder; Crooks, Pauline; Gould, Clare; Jones, Kimberley; Griffiths, Lyn R; Talaulikar, Dipti; Jain, Sanjiv; Tobin, Josh; Gandhi, Maher K Journal: Lancet Issue: Volume 2:Issue 10(2015) Page Start: e445 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗